Literature DB >> 8682603

Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis.

M Paradiso1, F Gabrielli, L Coppotelli, G Aguglia, M Pergolini, M Leonardo, S Basili, E Alcini, C Masala, C Cordova.   

Abstract

To assess the myocardial involvement in progressive systemic sclerosis we evaluated the presence of late potentials by signal-averaged electrocardiography (signal-averaged ECG) and the left ventricular function by M-mode, two dimensional and Doppler echocardiography. Fifteen outpatients, 7 with diffuse progressive systemic sclerosis and 8 with CREST syndrome variant, without clinical or electrocardiographic evidence of cardiac disease were studied and compared with 18 normal subjects. Late potentials occurred in 5 out of 15 progressive systemic sclerosis patients (33%) with a significant difference versus controls (P < 0.05) and were present only in the patients with diffuse progressive systemic sclerosis (P < or = 0.001 vs. controls). All progressive systemic sclerosis patients showed a normal left ventricular systolic function. Abnormal left ventricular filling was found in 9 progressive systemic sclerosis patients (5 with diffuse progressive systemic sclerosis and 4 with CREST). A more severe impairment of the mean values of diastolic function indexes was found in diffuse progressive systemic sclerosis than in CREST. In all diffuse progressive systemic sclerosis patients at least one method showed altered results, whereas half the CREST patients showed no pathological findings with both techniques. These results confirm a lower myocardial involvement in the CREST syndrome than in diffuse progressive systemic sclerosis and consequently this is probably related to a better prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 8682603     DOI: 10.1016/0167-5273(95)02521-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

Review 1.  Arrhythmias in pulmonary arterial hypertension.

Authors:  Archana Rajdev; Hasan Garan; Angelo Biviano
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.